Relapsing Multiple Sclerosis Clinical Trial
Official title:
A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) in Patients With Relapsing Multiple Sclerosis [AIOLOS]
This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable Disease-modifying Therapy (DMT) for Relapsing Multiple Sclerosis in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to approx. two years of treatment. Additionally, medical history of participants will be collected including disease duration, EDSS, MRI parameters and relapses.
The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study. The prospective observational period per patient will be up to approx. two years from the time of consent (2 years +2 months visit window). The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04121065 -
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
|
||
| Active, not recruiting |
NCT03996291 -
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT04510220 -
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT02241785 -
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
|
Phase 4 | |
| Completed |
NCT02792218 -
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01412333 -
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT03257358 -
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
|
Phase 4 | |
| Completed |
NCT01628393 -
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT04626921 -
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02234869 -
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
|
Phase 4 | |
| Withdrawn |
NCT05077956 -
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04486716 -
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04121403 -
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
|
Phase 3 | |
| Recruiting |
NCT05809986 -
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
|
||
| Terminated |
NCT00988052 -
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
|
Phase 3 | |
| Active, not recruiting |
NCT05232825 -
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT01047319 -
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT04847596 -
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
||
| Completed |
NCT01006941 -
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
|
Phase 2 | |
| Completed |
NCT01127750 -
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
|
Phase 3 |